Scandion Oncology ready for phase II with SCO-101

Scandion Oncology’s candidate SCO-101 is being developed to fight resistance to cancer drugs and is ready to enter phase II clinical trials. Metastatic colorectal cancer patients will be the first to be tested ... LÄS MER!